Volume 13, Issue 8 (9-2015)                   IJRM 2015, 13(8): 461-472 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ebrahimi M, Akbari Asbagh F. The role of autoimmunity in premature ovarian failure. IJRM. 2015; 13 (8) :461-472
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-677-en.html
1- Department of Obstetrics and Gynecology, Moheb-e-Yas Women General Hospital, Faculty of Medicine, Tehran University of Medical Sciences and Health Services, Tehran, Iran , Maeb214@yahoo.com
2- Department of Obstetrics and Gynecology, Moheb-e-Yas Women General Hospital, Faculty of Medicine, Tehran University of Medical Sciences and Health Services, Tehran, Iran
Abstract:   (655 Views)
Premature ovarian failure (POF) is a heterogeneous syndrome with several causative factors. Autoimmune mechanisms are involved in pathogenesis of 4-30 % of POF cases. The present review focuses on the role of autoimmunity in the pathophysiology of POF. The evidences for an autoimmune etiology are: demonstration of ovarian autoantibodies, the presence of lymphocytic oophoritis, and association with other autoimmune disorders. Several ovarian antigenic targets have been identified in POF patients. The oocyte seems to be the most often targeted cell. Lymphocytic oophoritis is widely present in POF associated adrenal insufficiency. Addisonۥs disease is one of the most common autoimmune disorders associated with POF. Early detection of this potentially life threatening disease was recommended in several studies. The gold standard for detecting autoimmune POF is ovarian biopsy. This procedure is not recommended due to unknown clinical value, expense, and risks. Several immunoassays have been proposed as substitute diagnostic tools. Nevertheless, there is no clinically proven sensitive and specific serum test to confirm the diagnosis of autoimmune POF or to anticipate the patient’s chance of developing POF or associated diseases. Some authors suggested the possible effects of immuno-modulating therapy on the resumption of ovarian function and fertility in a selected group of autoimmune POF patients. However, in most instances, this treatment fails to reverse the course of the disease. Numerous studies illustrated that standard treatment outcome for infertility is less effective in the presence of ovarian autoimmunity. The antibody-induced damage could be a pathogenic factor. Nevertheless, the precise cause remains obscure.
Full-Text [PDF 163 kb]   (176 Downloads) |   |   Full-Text (HTML)  (136 Views)  
Type of Study: Original Article |

References
1. Ebrahimi M, Akbari Asbagh F. Pathogenesis and causes of premature ovarian failure: An update. Int J Fertil Steril 2011; 5: 54-65.
2. Khole V. Does ovarian autoimmunity play a role in the pathophysiology of premature ovarian insufficiency? J Midlife Health 2010; 1: 9-13. [DOI:10.4103/0976-7800.66986]
3. Rees M, Purdie D. Premature menopause. In: Rees M, Purdie D, editors, Management of the menopause: the handbook. London: Royal Society of Medicine Press Ltd; 2006; 142-149.
4. Pal L, Santoro N. Premature ovarian failure (FOF): discordance between somatic and reproductive aging. Ageing Res Rev 2002; 1: 413-423. [DOI:10.1016/S1568-1637(02)00009-0]
5. Nelson LM. Primary ovarian insufficiency. N Engl J Med 2009; 360: 606-614. [DOI:10.1056/NEJMcp0808697]
6. The Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril 2006; 86: 148-155. [DOI:10.1016/j.fertnstert.2006.08.013]
7. Taylor AE . Systemic adversities of ovarian failure. J Soc Gynecol investing 2001;8: S7-S9.
8. Akbari asbagh F, Ebrahimi M. A case report of spontaneous pregnancy during hormonal replacement therapy for premature ovarian failure. Iran J Reprod Med 2011; 9: 47-49.
9. Nelson LM, Bakalov VK. Mechanisms of follicular dysfunction in 46,XX spontaneous premature ovarian failure. Endocrinol Metab Clin North Am 2003; 32: 613-637. [DOI:10.1016/S0889-8529(03)00043-4]
10. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod update 2005; 11: 391-410. [DOI:10.1093/humupd/dmi012]
11. Albright F, Smith PH, Fraser R. A syndrome characterized by primary ovarian insufficiency and decrease stature. Am J Med Sci 1942; 204: 625-648. [DOI:10.1097/00000441-194211000-00001]
12. Alzubadi NH, Chapin HL, Vanderhoof VH, Calis KA, Nelson LM. Meeting the needs of young women with secondary amenorrhea and spontaneous ovarian failure. Obstet Gynecol 2002; 99: 720-725.
13. Panay N, Kalu E. Management of premature ovarian failure. Best Prac Res Clin Obstet Gynecol 2009; 23: 129-140. [DOI:10.1016/j.bpobgyn.2008.10.008]
14. Dragojevic-Dikic S, Marisavljevic D, Mitrovic A, Dikic S, Jovanovic T, Jankovic-Raznatovic S. An immunological insight into premature ovarian failure (POF). Autoimmune Rev 2010; 9: 771-774. [DOI:10.1016/j.autrev.2010.06.008]
15. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi ethnic population study of the menopause transition. Hum Reprod 2003; 18: 199-206. [DOI:10.1093/humrep/deg005]
16. Beck-Peccoz P, Persani L. Premature ovarian failure. Orphanet J Rare Dis 2006; 6: 1-9.
17. Nolting M, Perez L. Belen M. Martinez Amuchastegui J. Straminsky V, Onetto Claudia C, et al. Importance of detecting transition to the premature ovarian failure. Gynecol Endocrinol 2008; 24: 257-258.
18. Lebovic D I, Naz R. Premature ovarian failure: Think "autoimmune disorder". Sex Reprod Menopause 2004; 2: 230-233. [DOI:10.1016/j.sram.2004.11.010]
19. Aittomaki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, et al. Mutation in the follicle-stimulating hormone receptor gene cause hereditary hypergonadotropic ovarian failure. Cell 1995; 82: 959-968. [DOI:10.1016/0092-8674(95)90275-9]
20. Laml T, Preyer O, Umek W, Hengstschlager M, Hanzal H. Genetic disorders in premature ovarian failure. Hum Reprod Update 2002; 8: 483-491. [DOI:10.1093/humupd/8.5.483]
21. Schlessinger D, Herrera I, Crisponi I, Mumm S, Percesepe A, Pellegrini M et al. Genetic and translocations involved in POF. Am J Med Genet 2002; 111: 328-333. [DOI:10.1002/ajmg.10565]
22. Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environment chemical. Nat Genet 2001; 28: 355-360. [DOI:10.1038/ng575]
23. Forges T, Monnier-Barbarino P, Faure GC, Bene M C. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update 2004; 10: 163-175. [DOI:10.1093/humupd/dmh014]
24. Rebar WR. Premature ovarian failure. Obstet Gynecol 2009; 113: 1355-1363. [DOI:10.1097/AOG.0b013e3181a66843]
25. Meskhi A, Seif MW. Premature ovarian failure. Curr Opin Obstet Gynecol 2006; 18: 418-426. [DOI:10.1097/01.gco.0000233937.36554.d3]
26. Tuohy VK, Altuntas CZ. Autoimmunity and premature ovarian failure. Curr Opin Obstet Gynecol 2007; 19: 366-369. [DOI:10.1097/GCO.0b013e328220e90c]
27. Conway SG, Christin- Maitre S. Premature ovarian failure. In: Fauser CJB, editor. Reproductive medicine molecular, cellular, and genetic fundamentals, New York: Parthenon Publishing: 2003; 587-599.
28. Yan G, Schoenfeld D, Penney C, Hurxthal K, Taylor AE, Faustman D. Identification of premature ovarian failure patients with underlying autoimmunity. J womens health Gend Based med 2000; 9: 275-287. [DOI:10.1089/152460900318461]
29. Novosad JA, Kalantaridou SN, Tong ZB, Nelson LM. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure. A controlled evaluation. BMC Womens Health 2003; 13: 2-9. [DOI:10.1186/1472-6874-3-2]
30. Luborsky JL. Ovarian autoimmune disease and ovarian autoantibodies. J Women's Health Gend Based Med 2002; 11: 585-599. [DOI:10.1089/152460902760360540]
31. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67: 604-606.
32. de Moraes Ruehsen M, Blizzard RM, Garcia-Bunuel R, Jones GS. Autoimmunity and ovarian failure. Am J Obstet Gynecol 1972; 112: 693-703. [DOI:10.1016/0002-9378(72)90797-1]
33. Kamada M, Hasebe H, Irahara M, Kinoshita T, Naka O, Mori T. Detection of anti-zona pellucid activities in human era by the passive hemaglutination reaction. Fertil Steril 1984; 41: 901-906. [DOI:10.1016/S0015-0282(16)47905-7]
34. Pires ES, Meherji PK, Vaidya RR, Parikh FR, Ghosalkar MN, Khole VV. Specific and sensitive immunoassays detect multiple anti-ovarian antibodies in women with infertility. J Histochem Cytochem 2007; 55: 1181-1190. [DOI:10.1369/jhc.7A7259.2007]
35. Falorni A, Laureti S, Candeloro P, Perrino S, Coronella C, Bizzarro A, et al. Steroid–cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril 2002; 78: 270-279. [DOI:10.1016/S0015-0282(02)03205-3]
36. Falorni A, Laureti S, Santeusanio F. Autoantibodies in autoimmune polyendocrine syndrome type II. Endocrinol Metab North Am 2002; 31: 369-389. [DOI:10.1016/S0889-8529(01)00010-X]
37. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997; 18: 107-134. [DOI:10.1210/er.18.1.107]
38. Sedmak DD, Hart WR, Tubbs RR. Autoimmune oophoritis: a histopathologic study of involved ovaries with immunologic characterization of the mononuclear cell infiltrate. Int J Gynecol Pathol 1987; 6: 73-81. [DOI:10.1097/00004347-198703000-00009]
39. Hill JA, Welch WR, Faris HM, Anderson DJ. Induction of class II major histocompatibility complex antigen expression in human granulose cells by interferon gamma: a potential mechanism contributing to autoimmune ovarian failure. Am J Obstet Gynecol 1990; 162: 534-540. [DOI:10.1016/0002-9378(90)90425-7]
40. Spremovic-Radienovic S. Laparoscopic ovarian biopsy in women with premature ovarian failure. 8th European congress on Menopause (EMAS). Maturitas 2009; 63: S1-136.
41. Poppe K, Velkeniers B. Female infertility and thyroid. Best Pract Res Clin Endocrinol Metab 2004; 18: 153-165. [DOI:10.1016/j.beem.2004.03.004]
42. Poppe K, Glinoer D, Toumaye H, Devroey P, Schiettecatte J, Haentijens P, et al. Thyroid autoimmunity and female infertility. Verh K Acad Geneeskd Belg 2006; 68: 357-377.
43. Cervera R, Balasch J. Bidirectional effects on autoimmunity and reproduction. Hum Reprod Update 2008; 14: 359-366. [DOI:10.1093/humupd/dmn013]
44. Tung ZB, Gold L, Pfeifer KE, Dorward H, Lee E, Bondy CA, et al. Mater, a maternal effect gene required for early embryonic development in mice. Nat Genet 2000; 26: 267-268. [DOI:10.1038/81547]
45. Monnier-Barbarino P, Forges T, Faure GC, Bene MC. Gonadal antibodies interfering with female reproduction. Best Pract Res Endocrinol Metab 2005; 19: 135-148. [DOI:10.1016/j.beem.2004.11.011]
46. Chernyshov VP, Radysh TV, Gura IV, Tatarshuk TP, Khominskaya ZB. Immune disorders in women with premature ovarian failure. Am J Reprod Immunol 2001: 46; 220-225. [DOI:10.1034/j.1600-0897.2001.d01-5.x]
47. Tung KSK, Garza KM, Lau Y, Bagavant H. Autoimmune ovarian disease:mechanism of induction and prevention. J Soc Gynecol Invest 2001; 8: 49-51.
48. Wu R, Van der Hook KH, Ryan NK, Norman RJ, Robker RL. Macrophage contributions to ovarian function. Hum Reprod Update 2004; 10: 119-133. [DOI:10.1093/humupd/dmh011]
49. Vallotton MB, Forbes AP. Antibodies to cytoplasm of ova. Lancet 1996; 2: 264-265.
50. Luborsky J L, Roussev R, Coulam C. Ovarian antibodies, FSH and inhibin are markers associated with unexplained infertility. Hum Reprod 2000; 15: 1046-1051. [DOI:10.1093/humrep/15.5.1046]
51. Luborsky J, Pong R. Pregnancy outcome and ovarian antibodies in infertility patients undergoing controlled ovarian hyperstimulation. Am J Reprod Immunol 2000; 44: 261-265. [DOI:10.1111/j.8755-8920.2000.440502.x]
52. Lawrence M. Primary ovarian insufficiency. N Eng J Med 2009; 360: 606-614. [DOI:10.1056/NEJMcp0808697]
53. Betterle C, Volpato M. Adrenal and ovarian autoimmunity. Eur J Endocinol 1998; 138: 16-25. [DOI:10.1530/eje.0.1380016]
54. Dal Pra C, Chen S, Furmaniak J, Rees Smith B, Pedini B, Moscon A, et al. Autoantibodies to steroidogenic enzymes in patients with premature ovarian failure with and without Addison's disease. Eur J Endocrinol 2003; 148: 565-570. [DOI:10.1530/eje.0.1480565]
55. Reato G, Morlin L, Chen S, Furmaniak J, Smith B Rees, Masiero S, et al. Premature ovarian failure in patients with autoimmune Addison, s disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab 2011; 96: 1255-1261. [DOI:10.1210/jc.2011-0414]
56. Bakalov VK, Anasti JN, Calis KA, Vanderhoof VH, Premkumar A, Chen S, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. Fertil Steril 2005; 84: 958-965. [DOI:10.1016/j.fertnstert.2005.04.060]
57. Gobert B, Jolivet-Reynaud C, Dalbon P, Barbario-Monnier P, Faure G, Jolivet M, et al. An immunoreactive peptide of the FSH involved in autoimmune infertility. Biochem Biophys Res Commun 2001; 289: 819-824. [DOI:10.1006/bbrc.2001.6059]
58. Anasti JN, Flack MR, Froethlich J, Nelson LM. The use of recombinant gonadotropin receptors to search for immunoglobulin G-mediated premature ovarian failure. J Clin Endocrinol Metab 1995; 80: 824-828.
59. Ryan MM, Jones HR Jr. Myasthenia gravis and premature ovarian failure. Muscle Nerve 2004; 30: 231-233. [DOI:10.1002/mus.20067]
60. Chiauzzi VA, Bussmann I, Calvo JC, Sundblad V, Charreau EH. Circulating immunoglobulins that inhibit the binding of follicle stimulating hormone receptor: A putative diagnostic role resistant ovarian syndrome. Clin Endocrinol (Oxf) 2004; 61: 46-54. [DOI:10.1111/j.1365-2265.2004.02054.x]
61. Koyama K, Hasegawa A. Premature ovarian failure syndrome may be induced by autoimmune reactions to zona pellucid proteins. J Reprod Endocrinol 2006; 3: 94-97.
62. Kinoshita A, Tanaka H, Komori S, Hasegawa A, Koyoma K. Autoimmunity to zona pellucida possibly causes premature ovarian failure (POF). J reprod Immunol 2006; 71: 155. [DOI:10.1016/j.jri.2006.08.035]
63. Damewood MD, Zacur HA, Hoffman GJ, Rock JA. Circulating antiovarian antibodies in premature ovarian failure. Obstet Gynecol 1986; 68: 850-854.
64. Luborsky JL, Visintin I, Boyers S, Asari T, Caldwell B, DeCherney A. Ovarian autoantibodies detected by immobilized antigens immunoassay in patients with premature ovarian failure. J Clin Endocrinol Metab 1990; 70: 69-75. [DOI:10.1210/jcem-70-1-69]
65. Paoto SG, Viana VS, Mendonca BB, Yoshinari NH, Bonfa E. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol 1999; 26: 1087-1093.
66. Sotsiou F, Bottazzo GF, Doniach D. Immunofluorescence studies on autoantibodies to steroid-producing cells, and to germline cells in endocrine disease and infertility. Clin Exp Immunol 1980; 39: 97-111.
67. Anderson JR, Goudie RB, Gray KG, Stuart Smith DA. Immuonological features of idiopathic Addison's disease: an antibody to cells producing steroid hormones. Clin Exper Immunol 1968; 3: 107-110.
68. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens and their applicability in diagnosis and disease prediction. Endocr Rev 2002; 23: 327-364. [DOI:10.1210/edrv.23.3.0466]
69. Perniola R, Falorni A, Clemente MG, Forini F, Accogli E, Lobergelio G. Organ-specific and non-organ–specific autoantibodies in children and young adult with autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy (APECED). Eur J Endocrinol 2000; 43: 97-503. [DOI:10.1530/eje.0.1430497]
70. Edassery SL, Shatavi SV, Kunkel JP, Hauer Ch, Brucker C, Penumatsa K, et al. Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure. Fertil Steril 2010; 94: 2636-2641. [DOI:10.1016/j.fertnstert.2010.04.012]
71. Chen S, Sawicka J, Betterle C, Powell M, Prentice L, Volpato M, et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab 1996; 81: 1871-1876.
72. Reimand K, Peterson P, Hyoty H, Uibo R, Cooke I, Weetman AP, et al. 3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure. J Clin Endocrinol Metab 2000; 85: 2324-2326.
73. Arif S, Vallian S, Farzaneh F, Zanone MM, James SL, Pietropaolo M, et al. Identification of 3β–hydroxysteroid dehydrogenase as a novel target of steroid cell antibodies association of autoantibodies with endocrine autoimmune disease. J Clin Endocrinol Metab 1996; 81: 4439-4445.
74. Scully RE, Mark EG, McNeely BU. Case records of the Massachusetts General Hospital. N Engl J Med. 1986; 315: 1336-1343.
75. Van Weissenbruch MM, Hoek A, Van Vliet-Bleeker I, Schoemaker J, Drexhage H. Evidence for existence of immunoglobulins that block ovarian granulose cell growth in vitro. A putative role in resistance ovary syndrome? J Clin Endocrinol Metab 1991; 73: 360-367. [DOI:10.1210/jcem-73-2-360]
76. Chiauzzi V, Cigorraga S, Escobar ME, Rivarola MA, Charreau EH. Inhibition of follicle-stimulating hormone receptor binding by circulating immunoglobulins. J Clin Endocrinol Metab 1982; 54: 1221-1228. [DOI:10.1210/jcem-54-6-1221]
77. Wheatcroft NJ, Toogood AA, Li TC, Cooke D, Weetman AP. Detection of antibodies to ovarian antigens in women with premature ovarian failure. Clin Exp Immunol 1994; 96: 122-128. [DOI:10.1111/j.1365-2249.1994.tb06241.x]
78. Pires E S. Multiplicity of molecular and cellular targets in human ovarian autoimmunity: an update. J Assist Reprod Genet 2010; 27: 519-524. [DOI:10.1007/s10815-010-9440-5]
79. Takamizawa S, Shibahara H, Shibayama T, Suzuki M. Detection of antizona pellucida antibodies in the sera from premature ovarian failure patients by a highly specific test. Fertil Steril 2007; 88: 925-932. [DOI:10.1016/j.fertnstert.2006.12.029]
80. Smith S, Hosid S. Premature ovarian failure associated with autoantibodies to the zona pellucida. Int J Fertil Menopausal Stud 1994; 39: 316-319.
81. Pires ES, Khole VV. A block in road to fertility: Autoantibodies to heat–shock protein 90-beta in human ovarian autoimmunity. Fertil Steril 2009; 92: 1395-1409. [DOI:10.1016/j.fertnstert.2008.08.068]
82. Nelson LM. Autoimmune ovarian failure: comparing the mouse model and the human disease. J Soc Gynecol Invest 2001; 8: S55-S57. [DOI:10.1177/1071557601008001S17]
83. Tong ZB, Nelson LM. Mater encodes a maternal protein in mice with a leucine–rich repeat domain homologous to porcine ribonuclease inhibitor. Mamm Genome 2000; 11: 281-287. [DOI:10.1007/s003350010053]
84. Tong ZB, Gold L, De Pol A, Vanevski A, Dorward H, Sena P, et al. Developmental expression and subcellular localization of mouse MATER, an oocyte-specific protein essential for embryo development. Endocrinol 2004; 145: 1427-1434. [DOI:10.1210/en.2003-1160]
85. Sundblad V, Bussmann L, Chiauzzi VA, Pancholi V, Charreau EH. Alpha-enolase: a novel autoantigen in patients with premature ovarian failure. Clin Endocrinol (Oxf) 2006; 65: 745-751. [DOI:10.1111/j.1365-2265.2006.02661.x]
86. Vidal CI, Mintz PJ, Lu K, Ellis LM, Manenti L, Chiavazzi R, et al. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients.Oncogene 2004; 23: 8859-8867. [DOI:10.1038/sj.onc.1208082]
87. Gitlits VM, Toh BH, Sentry JW. Disease association, origin, and clinical relevance of autoantibodies to the glycolytic enzyme enolase. J Investig Med 2001; 49: 138-145. [DOI:10.2310/6650.2001.34040]
88. Pashov A, Kenderov A, Kyukchiev S, Kehayov I, Hristova S, Lacroix-Desmazes S,et al. autoantibodies to heat shock protein 90 in the human natural antibody repertoire .Int Immunol 2002; 14: 453-461. [DOI:10.1093/intimm/14.5.453]
89. Li WH, Zhao J, Li HY, Liu H, Li AL, Wang HX, et al. Proteomics-based identification of autoantibodies in the sera of healthy Chinese individuals from Beijing. Proteomics 2006; 6: 4781-4789. [DOI:10.1002/pmic.200500909]
90. Panchli V. Multifunctional alpha-enolase: its role in disease. Cell Mol Life Sci 2001; 58: 902-920. [DOI:10.1007/PL00000910]
91. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005; 30: 142-150. [DOI:10.1016/j.tibs.2005.01.005]
92. Betterle C, Volpato M, Pedini B, Chen S, Smith BR, Furmaniak J. Adrenal cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease: comparison of immunoflurescence and immunoprecipitation assays. J Clin Endocrinol Metab 1999; 84: 618-622.
93. Tanaka H, Perez MS, Powell M, Sanders JF, Sawicka J, Chen S, et al. Steroid 21-hydroxylase autoantibodies: measurement with a new immunoprecipitation assay. J Clin Endocrinol Metab 1997; 82: 1440-1446. [DOI:10.1210/jc.82.5.1440]
94. Kelkar RL, Meherji PK, Kadam SS, Gupta SK, Nandedkar TD. Circulating auto-antibodies against the zona pellucid and thyroid microsomal antigen in women with premature ovarian failure. J Reprod Immunol 2005; 66: 53-67. [DOI:10.1016/j.jri.2005.02.003]
95. Luborsky J, Llanes B, Davies S, Binor Z, Radwanska E, Pong R. Ovarian autoimmunity: greater frequency of autoantibodies in premature menopause and unexplained infertility than in general population. Clin Immunol 1999; 90: 368-374. [DOI:10.1006/clim.1998.4661]
96. Luborsky J L. Ovarian autoimmune disease and ovarian autoantibodies. J Women's Health Gend Based Med 2002; 11: 585-599. [DOI:10.1089/152460902760360540]
97. Pires ES, Parte PP, Meherji PK, Khan SA, Khole VV. Naturally occurring Anti-albumin antibodies are responsible for false positivity in diagnosis of autoimmune premature ovarian failure. J Histochem Cytochem 2006; 54: 397-405. [DOI:10.1369/jhc.5A6778.2005]
98. Bats AS, Barbarino P, Bene M C, Faure GC, Forges T. Local lymphocytic and epithelial activation in a case of autoimmune oophoritis. Fertil Stertil 2008; 90: 849. [DOI:10.1016/j.fertnstert.2007.08.048]
99. Gloor E, Hurlimann J. Autoimmune oophoritis. Am J Clin Pathol 1984; 81: 105-109. [DOI:10.1093/ajcp/81.1.105]
100. Bannatyne P, Russell P, Shearman RP. Autoimmune oophoritis: a clinical assessment of 12 cases. In J Gynecol Pathol 1990; 9: 191-207. [DOI:10.1097/00004347-199007000-00001]
101. Fenichel P. Premature ovarian failure: anautoimmune disease? In: Genazzani RA, Petraglia F, Artini GP, editors. Advances in gynecological endocrinology. New York: Parthenon Publishing: 2002; 143-149.
102. Massin N, Gougeon A, Meduri G, Thibaud E, Laborde K, Matuchansky C, et al. Significance of ovarian histology in the management of patients presenting a premature ovarian failure. Hum Reprod 2004; 19: 2555-2560. [DOI:10.1093/humrep/deh461]
103. Lass A. Assessment of ovarian reserve- is there a role for ovarian biopsy? Hum Reprod 2001; 16: 1055-1057. [DOI:10.1093/humrep/16.6.1055]
104. Perheentupa J. APS-1/ APECED: the clinical disease and therapy. Endocrinol Metab Clin N Am 2002; 31: 295-320. [DOI:10.1016/S0889-8529(01)00013-5]
105. Schatz DA, Winter WE. Autoimmune polyglandular syndrome II: clinical syndrome and treatment. Endocrinol Metab Clin N Am 2002; 31: 339-352. [DOI:10.1016/S0889-8529(01)00012-3]
106. Poppe K, Glinoer D, Van Steirteghem A, Tournaye H, Devroey P, Schiettecatte J, et al. Thyroid dysfunction and autoimmunity in infertile women. Thyroid 2002; 12: 997-1001. [DOI:10.1089/105072502320908330]
107. Abalovich M, Mitelberg L, Allami C, Gutierrez S, Alcaraz G, Otero P. Subclinical hypothyroidism and thyroid autoimmunity in women with infertility. Gynecol Endocrinol 2007; 23: 279-283. [DOI:10.1080/09513590701259542]
108. Bakalov VK, Vanderhoof VH, Bondy C A, Nelson L M. Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod 2002; 17: 2096-2100. [DOI:10.1093/humrep/17.8.2096]
109. Ambrosi B, Barbetta L, Morricone L. Diagnosis and management of Addison's disease in pregnancy. J Endcrinol Invest 2003; 26: 698-702. [DOI:10.1007/BF03347034]
110. Maclaren N, Chen QY, Kukrejia A, Marker J, Zhang CH, Sun ZS. Autoimmune hypogonadism. J Soc Gynecol Invest 2001; 8: 52-54. [DOI:10.1177/1071557601008001S16]
111. Kauffmann RP, Castracane VD. Premature ovarian failure associated with autoimmune polyglandular syndrome: pathophysiological mechanisms and future fertility. J Womens Health (Larchmt) 2003; 12: 513-520. [DOI:10.1089/154099903766651649]
112. Gleicher N, Weghofer A, Barad HD. A pilot study of premature ovarian senescence: Different genotype and phenotype for genetic and autoimmune etiologies. Fertil Steril 2009; 91: 1707-1711. [DOI:10.1016/j.fertnstert.2008.01.099]
113. Tsigkou A, Marzotti S, Borges L, Brozzetti A, Reis F, Candeloro P, et al. High serum inhibin concentration discriminates autoimmune oophoritis from other forms of primary ovarian insufficiency. J Clin Endocrinol Metab 2008; 93: 1263-1269. [DOI:10.1210/jc.2007-1675]
114. Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril 2001; 76: 223-231. [DOI:10.1016/S0015-0282(01)01878-7]
115. Horejesi J, Martinek J, Novakova D, Madar J, Brandejska M. Autoimmune antiovarian antibodies and their impact on the success of an IVF/ET program. Ann NY Acad Sci 2000; 900: 351-356. [DOI:10.1111/j.1749-6632.2000.tb06248.x]
116. Forges T, Monnier-Barbarino P,Guillet-May F, Faure GC, Bene MC. Corticosteroids in patients with antiovarian antibodies undergoing in vitro fertilization: a prospective pilot study. Eur J Clin Pharmacol 2006; 62: 699-705. [DOI:10.1007/s00228-006-0169-0]
117. Monnier-Barbarino P, Jouan C, Dubois M, Gober B, Faure GC, Bene MC. Antiovarian antibodies and in vitro fertilization: cause or consequence? Gynecol Obstet Fertil 2003; 31: 770-773. [DOI:10.1016/S1297-9589(03)00209-1]
118. Meyer WR, Lavy G, DeCherney AH, Vinstin I, Economy K, Lubersky JL. Evidence of gonadal and gonadotropin antibodies in women with a suboptimal ovarian response to exogenous gonadotropin. Obstet Gynecol 1990; 75: 795-799.
119. Koyama K, Hasegawa A, Inoue M, Isojima S. Blocking of human sperm-zona interaction by monoclonal antibodies to a glycoprotein family (ZP4) of porcine zona pellucid. Biol Reprod 1991; 45: 727-735. [DOI:10.1095/biolreprod45.5.727]
120. Sivapurapu N, Upadhyay A, Hasegawa A, Koyama K, Gupta SK. Native zona pellucid reactivity and in-vitro effect on human sperm–egg binding with antisera against bonnet monkey ZP1 and ZP3 synthetic peptides. J Reprod Immunol 2002; 56: 77-91. [DOI:10.1016/S0165-0378(02)00023-2]
121. Mantzavinos T, Dalamanga N, Hassiakos D, Dimitriadou F, Konidaris S, Zourlas PA. Assessment of autoantibodies to the zona pellucida in serum and follicular fluid in–vitro fertilization patients. Clin Exp Obstet Gynecol 1993; 20: 111-115.
122. Papale ML, Grillo A, Leonardi E, Giuffrida G, Palumbo M, Palumbo G. Assessment of the relevance of zona pellucida antibodies in follicular fluid of in-vitro fertilization (IVF) patients. Hum Reprod 1994; 9: 1827-1831. [DOI:10.1093/oxfordjournals.humrep.a138342]
123. Mardesic T, Ulcova-Gallova Z, Huttelova R, Muller P, Voboril J, Mikova M, et al. The influence of different types of antibodies on in vitro fertilization results. Am J Reprod Immunol 2000; 43: 1-5. [DOI:10.1111/j.8755-8920.2000.430101.x]
124. Van Kasteren YM, Braat DDM, Hemrika DJ, Lambalk CB, Rekers–Mlombrag LTM, Von Blomberg BME, et al. Corticostroids do not influence ovarian responsiveness to gonadotropins in patients with premature ovarian failure: a randomized, placebo-controlled trial. Fertil Steril 1999; 71: 90-95. [DOI:10.1016/S0015-0282(98)00411-7]
125. Corenblum B, Rowe T, Taylor PJ. High dose, short-term glucocorticoids for the treatment of infertility resulting from premature ovarian failure. Fertil Steril 1993; 59: 988-991. [DOI:10.1016/S0015-0282(16)55915-9]
126. Wang L, Huang P, Huang X, [Analysis of the treatment of 1,020 patients with immunologic infertility] Zhonghua Fu Chan Ke Za Zhi 1999; 34: 234-236. (in Chinese).
127. Barbarino-Monnier P, Gobert B, Guillet-May F, Bene MC, Barbarino A, Foliguet B, et al. Ovarian autoimmunity and corticotherapy in an in-vitro-fertilization attempt. Hum Reprod 1995; 10: 2006-2007. [DOI:10.1093/oxfordjournals.humrep.a136225]
128. Levesque MC. Translational mini-review series B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 2009; 157: 198-208. [DOI:10.1111/j.1365-2249.2009.03979.x]
129. Corenblum B, Rowe T, Taylor PJ. High-dose, short-term glucocorticoids for the treatment of infertility resulting from premature ovarian failure. Fertil Steril 1993; 59: 988-991. [DOI:10.1016/S0015-0282(16)55915-9]
130. Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertil Steril 2009; 91: 644-646. [DOI:10.1016/j.fertnstert.2007.11.055]
131. Barad D, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril 2005; 84: 756. [DOI:10.1016/j.fertnstert.2005.02.049]
132. Kalantaridou SN, Braddock DT, Patronas NJ, Nelson LM. Treatment of autoimmune premature ovarian failure. Hum Reprod 1999; 14: 1777-1782. [DOI:10.1093/humrep/14.7.1777]
133. Burger HG. Androgen production in women. Fertil Steril 2002; 77: S3-5. [DOI:10.1016/S0015-0282(02)02985-0]
134. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006; 21: 2845-2849. [DOI:10.1093/humrep/del254]
135. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007; 24: 629-634. [DOI:10.1007/s10815-007-9178-x]
136. Kalu E, Panay N. Spontaneous premature ovarian failure: management challenge. Gynecol Endocrinol 2008; 24: 273-279. [DOI:10.1080/09513590801990764]

Send email to the article author


© 2020 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb